Abstract
Migraine is a neurological condition that can interfere with every aspect of daily life. The calcitonin gene-related peptide receptor (CGRP) antagonists, such as Erenumab, bring a novel therapeutic approach to migraine management. This study aims to evaluate the Quality of Life (QoL) and mood in a sample of patients diagnosed with migraine and prophylactically treated with Erenumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
